Autosomal Recessive Infantile Hypercalcemia (ARIH

Autosomal recessive infantile hypercalcemia is a rare genetic disease that makes blood calcium high in babies and sometimes in older children or adults. Two main gene problems cause it. The first is CYP24A1. This gene normally breaks down active vitamin D. If it does not work, active vitamin D stays high. Gut absorbs more calcium. Blood calcium rises. Urine calcium rises. Calcium can deposit in kidneys. The second is SLC34A1, a kidney phosphate transporter. When this fails, kidneys waste phosphate. Low phosphate signals the body to make more active vitamin D. Calcium then goes up. Symptoms include vomiting, constipation, poor weight gain, dehydration, and kidney stones or nephrocalcinosis. Early reports and modern genetics confirmed the cause in both genes. BioMed Central+5New England Journal of Medicine+5OUP Academic+5

Vitamin D has inactive and active forms. The body tightly controls these. When calcium falls, parathyroid hormone (PTH) rises and the kidney makes more active vitamin D to raise calcium. In ARIH due to CYP24A1, the enzyme that deactivates active vitamin D is broken. Active vitamin D becomes too high even when PTH is low. In ARIH due to SLC34A1, kidney phosphate loss pushes the body to make extra active vitamin D. In both cases, intestines absorb excess calcium, kidneys spill calcium, and calcium can form stones. NCBI+1

Autosomal recessive infantile hypercalcemia (ARIH) is a rare genetic condition that makes a baby or young child absorb and keep too much calcium. Blood calcium rises (hypercalcemia), the kidneys spill extra calcium into urine (hypercalciuria), and calcium can deposit inside the kidneys (nephrocalcinosis) or form stones (nephrolithiasis). The most common reasons are harmful changes (variants) in two genes: CYP24A1 and SLC34A1. These genes control vitamin D breakdown and kidney phosphate handling. When they fail, the active vitamin D hormone becomes too high or phosphate becomes too low, and the body pulls in too much calcium. This can cause vomiting, poor weight gain, dehydration, constipation, excessive urination and thirst, kidney problems, and sometimes bone issues. In many babies, problems appear soon after vitamin D drops are started or after heavy sun exposure, because their bodies cannot safely handle vitamin D. New England Journal of Medicine+2PubMed+2

Other names

• Idiopathic infantile hypercalcemia (IIH) – an older term often used for the same condition.

• Infantile hypercalcemia type 1 (HCINF1) – due to CYP24A1 variants (vitamin D 24-hydroxylase deficiency).

• Infantile hypercalcemia type 2 (HCINF2) – due to SLC34A1 variants (renal phosphate transporter NaPi-IIa).

• Vitamin D hypersensitivity due to CYP24A1 deficiency – another clinical label used in reports. MedlinePlus+2MedlinePlus+2

Types

Type 1 (HCINF1 – CYP24A1-related).
The CYP24A1 enzyme normally breaks down both 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D (the active hormone). When this enzyme is missing or weak, the active hormone builds up. The intestine then absorbs too much calcium, blood calcium rises, parathyroid hormone (PTH) is suppressed, and the kidneys excrete a lot of calcium. Babies are very sensitive to normal vitamin D doses and to sunlight. New England Journal of Medicine+1

Type 2 (HCINF2 – SLC34A1-related).
The SLC34A1 gene encodes a kidney phosphate transporter (NaPi-IIa). If it does not work, the kidneys lose phosphate into urine. Low blood phosphate stimulates more active vitamin D, which again drives calcium absorption and hypercalcemia. In short: low phosphate → high active vitamin D → high calcium. PubMed+1

---

Causes

ARIH is genetic. The “root causes” are the gene changes. Many day-to-day things then trigger or worsen high calcium in children who carry those gene changes.

1. Biallelic CYP24A1 variants (HCINF1).
   Having harmful variants in both copies of CYP24A1 blocks vitamin D breakdown. This is the classic genetic cause. New England Journal of Medicine

2. Biallelic SLC34A1 variants (HCINF2).
   Two harmful SLC34A1 variants reduce phosphate reabsorption in the kidney and raise active vitamin D. PubMed

3. Compound heterozygosity.
   Two different harmful variants in the same ARIH gene (one on each copy) can cause disease; this is common in recessive disorders. PubMed

4. Functionally significant single-allele variants.
   Some people with one strong variant in CYP24A1 or SLC34A1 can still develop symptoms (often milder) like stones and nephrocalcinosis. BioMed Central

5. Routine vitamin D supplementation.
   Normal infant vitamin D drops can trigger hypercalcemia in CYP24A1 deficiency because the body cannot deactivate vitamin D properly. PubMed

6. High dietary vitamin D intake.
   Fortified foods or extra vitamins increase the vitamin D load and can push calcium higher in ARIH. New England Journal of Medicine

7. Intense sunlight/UV exposure.
   More skin vitamin D production can raise active vitamin D levels in CYP24A1 deficiency. New England Journal of Medicine

8. Low phosphate intake or losses.
   In SLC34A1 disease, any extra fall in phosphate (dietary or urinary) further boosts active vitamin D and calcium absorption. PubMed

9. Dehydration.
   Less body water concentrates blood calcium and increases kidney stone risk. (General clinical principle in hypercalcemia.)

10. Thiazide diuretics.
    These reduce urinary calcium excretion and may worsen hypercalcemia/hypercalciuria; they are generally avoided in ARIH.

11. Prolonged immobilization.
    Can release calcium from bone and add to high calcium levels.

12. High-calcium formula or foods.
    Extra oral calcium intake may aggravate hypercalcemia when vitamin D is high.

13. Granulomatous disease (if present).
    Conditions that make extra active vitamin D can layer on top of ARIH and intensify hypercalcemia.

14. Pregnancy in affected adults.
    Maternal CYP24A1 variants can cause significant hypercalcemia during pregnancy and affect the newborn. MDPI+1

15. Certain antifungals or antibiotics stopped after use.
    Stopping drugs like ketoconazole or rifampin (when they had been suppressing vitamin D activation or enhancing breakdown) can allow calcium to rebound. PMC+1

16. High vitamin D injections or megadose therapy.
    Massive doses can be dangerous in CYP24A1 deficiency because deactivation is blocked. New England Journal of Medicine

17. Very low salt intake with dehydration.
    Can reduce kidney calcium flushing and favor stone formation.

18. Genetic background (modifier genes).
    Some families show different severity despite similar variants, suggesting modifiers; case series note variable expressivity. Frontiers

19. Infant age and growth bursts.
    Early infancy (when vitamin D prophylaxis begins) is a typical time for first symptoms. PubMed

20. Coexisting kidney issues.
    Any kidney problem that reduces urine flow or changes mineral handling can worsen nephrocalcinosis risk in ARIH.

---

Symptoms and signs

1. Poor feeding and vomiting.
   High calcium slows the gut and causes nausea; babies spit up more and feed less. PubMed

2. Constipation.
   Hypercalcemia reduces intestinal motility, so stools become hard and infrequent. PubMed

3. Dehydration.
   Excess calcium causes the kidneys to lose water (a “diuresis”), so babies get dry and tired.

4. Excessive urination (polyuria) and thirst (polydipsia).
   Parents may notice very wet diapers and a baby who wants to drink often.

5. Irritability or lethargy.
   High calcium can affect the brain, leading to fussiness or sluggishness.

6. Poor weight gain / failure to thrive.
   Eating less and losing fluids make growth lag behind expected curves. PubMed

7. Abdominal pain.
   Older infants or toddlers may point to tummy pain from constipation or stones.

8. Blood in urine (hematuria).
   Kidney stones can scratch the urinary tract and cause visible or microscopic blood.

9. Back or flank pain (in older toddlers/children).
   Suggests stones moving in the urinary tract.

10. Muscle weakness or low tone.
    Calcium imbalance can affect muscle function, making babies feel “floppy.”

11. Bone pain or tenderness.
    Remodeling changes and altered vitamin D can affect bones; some children need evaluation for mineral density. OUP Academic

12. High blood pressure (sometimes).
    Long-standing kidney calcium deposits can affect kidney function and blood pressure.

13. No fever but “sick-looking.”
    These babies can look unwell without signs of infection.

14. Recurrent kidney stones or nephrocalcinosis.
    A key clue in older children and even adults—sometimes the first sign. BioMed Central

15. Normal or high vitamin D on labs with low PTH.
    Doctors often notice suppressed PTH alongside high or inappropriately normal active vitamin D.

---

Diagnostic tests

A) Physical exam (at the bedside)

1. General appearance and hydration check.
   The clinician looks for dry mouth, sunken eyes, decreased tears, and skin “tenting” that suggest dehydration from calcium-induced diuresis.

2. Growth measurements.
   Weight, length/height, and head circumference are plotted on growth charts to see if growth is lagging (failure to thrive).

3. Vital signs (heart rate, blood pressure, temperature).
   High calcium and kidney issues can affect heart rate and blood pressure; fever is usually absent unless there’s infection.

4. Abdominal and flank exam.
   Gentle pressing may reveal discomfort; flank tenderness can hint at stones.

5. Muscle tone and general neurologic check.
   Low tone, lethargy, or irritability can be related to hypercalcemia.

B) “Manual” clinical assessments (simple bedside checks clinicians perform)

6. Intake–output diary.
   Parents track feeds and diapers; excessive urine points to a calcium-related diuresis.

7. Stool diary and palpation for stool burden.
   Documents constipation and helps guide supportive care.

8. Diet and supplement review.
   Confirms vitamin D drops, fortified foods, or extra calcium that may worsen ARIH. PubMed

9. Sunlight/UV exposure history.
   Extra UV can raise vitamin D, important in CYP24A1 disease. New England Journal of Medicine

10. Medication review.
    Checks for thiazide diuretics or other drugs that could worsen hypercalcemia or alter vitamin D handling.

C) Laboratory and pathological tests

11. Serum total and ionized calcium.
    Confirms hypercalcemia (the core problem) and its severity.

12. Parathyroid hormone (PTH).
    Usually low or suppressed in ARIH because high calcium shuts PTH down. Frontiers

13. 25-hydroxyvitamin D [25(OH)D].
    May be normal or high, depending on intake, but by itself does not explain the disorder.

14. 1,25-dihydroxyvitamin D [1,25(OH)₂D].
    Often inappropriately high for the calcium level in ARIH, because breakdown is blocked (CYP24A1) or phosphate is low (SLC34A1). Frontiers

15. Serum phosphate and alkaline phosphatase.
    Phosphate can be low in SLC34A1 disease; bone enzyme levels help assess bone turnover. PubMed

16. Spot urine calcium/creatinine ratio or 24-hour urine calcium.
    Shows hypercalciuria, which raises risk of stones and nephrocalcinosis.

17. The 25(OH)D-to-24,25(OH)₂D ratio (specialized test).
    In CYP24A1 deficiency, 24,25(OH)₂D is very low, so the ratio is markedly elevated; this helps confirm the enzyme defect. Mayo Clinic

18. Renal function tests (creatinine, electrolytes; urine analysis).
    Looks for kidney injury, hematuria, crystals, or infection.

19. Genetic testing (CYP24A1, SLC34A1).
    Sequencing identifies the exact variants and confirms the type (HCINF1 vs HCINF2). Testing is recommended when infants have otherwise unexplained hypercalcemia with low PTH and high 1,25(OH)₂D, or when nephrocalcinosis is found early. New England Journal of Medicine+1

20. Electrocardiogram (ECG).
    Marked hypercalcemia can shorten the QT interval and, in severe cases, affect heart rhythm; an ECG is a quick safety check.

D) Imaging tests

• Renal ultrasound.
  First-line imaging to detect nephrocalcinosis (calcium deposits) and nephrolithiasis (stones) without radiation. This is a key test in ARIH. OUP Academic

• Kidney/urinary tract CT (low-dose or limited when possible).
  Sometimes needed if ultrasound is unclear and stones are strongly suspected.

• Skeletal survey or targeted X-rays (if indicated).
  Used when bone pain, fractures, or rickets-like changes are suspected.

• DXA (bone density) in older children/adults with persistent issues.
  Assesses bone mineral density when long-term imbalances or fractures are concerns.

Non-pharmacological treatments (therapies and other measures)

1. Stop all vitamin D supplements. This is the first step. It lowers the input that drives high calcium. Purpose: reduce vitamin D load. Mechanism: less substrate for activation. Expert reviews recommend strict avoidance. MDPI

2. Limit high-calcium foods temporarily (clinician-directed). Purpose: reduce absorbed calcium during a flare. Mechanism: less intestinal calcium available while vitamin D tone is high. Guidance derives from vitamin-D–mediated hypercalcemia management principles. NCBI

3. Hydration with oral fluids. Purpose: protect kidneys and increase calcium excretion. Mechanism: more urine flow lowers calcium concentration and stone risk. NCBI

4. Intravenous isotonic fluids in acute crises (hospital setting). Purpose: correct dehydration and lower calcium quickly. Mechanism: increases glomerular filtration and calciuresis. NCBI

5. Avoid thiazide diuretics. Purpose: prevent worsening hypercalcemia because thiazides increase renal calcium reabsorption. Mechanism: distal tubule effect. Thiazide-associated hypercalcemia is well described. PMC

6. Sunlight moderation. Purpose: reduce skin production of vitamin D. Mechanism: less UV-B driven cholecalciferol lowers active vitamin D generation pathway in susceptible patients. Pregnancy literature emphasizes this in CYP24A1 deficiency. MDPI

7. Kidney ultrasound surveillance. Purpose: detect nephrocalcinosis or stones early. Mechanism: imaging tracks calcium deposition and guides treatment intensity. PMC

8. Urine calcium/creatinine and 24-hour urine monitoring. Purpose: follow hypercalciuria. Mechanism: track response to therapy and stone risk. NCBI

9. Nutritionist-guided diet to avoid excess calcium and vitamin D. Purpose: safe calorie intake while controlling minerals. Mechanism: structured planning to avoid hidden vitamin D and high-calcium foods during active disease. MDPI

10. Phosphate repletion in SLC34A1-related disease (clinician-directed). Purpose: correct renal phosphate loss and blunt excess 1,25-vitamin D production. Mechanism: restores phosphate to reduce calcitriol drive. Case reports highlight its role. e-apem.org

11. Kidney stone prevention counseling. Purpose: reduce stone risk. Mechanism: fluids, citrate sources, and trigger avoidance support renal health. NCBI

12. Genetic counseling for families. Purpose: explain inheritance and recurrence risk. Mechanism: autosomal recessive risk assessment and testing of relatives when appropriate. New England Journal of Medicine

13. Medication review for interactions. Purpose: avoid drugs that raise vitamin D or calcium. Mechanism: remove contributors such as high-dose vitamin D or calcium-containing antacids. NCBI

14. Monitoring during intercurrent illness. Purpose: dehydration worsens hypercalcemia risk. Mechanism: early IV fluids and labs if intake is poor. NCBI

15. Pregnancy-specific planning in CYP24A1. Purpose: prevent maternal and fetal complications. Mechanism: avoid vitamin D supplements and monitor calcium closely. MDPI

16. Sun-protective clothing and timing of outdoor play. Purpose: practical sunlight moderation in infants and children. Mechanism: reduces cutaneous vitamin D synthesis. MDPI

17. Education to check fortified foods. Purpose: avoid hidden vitamin D sources (formula changes only under clinician advice). Mechanism: label awareness lowers inadvertent intake. MDPI

18. Regular blood tests (calcium, phosphate, creatinine, 25-OH-D, 1,25-OH2-D, PTH). Purpose: track disease control. Mechanism: detect biochemical shifts early. OUP Academic

19. Nephrology follow-up for nephrocalcinosis. Purpose: preserve kidney function long term. Mechanism: proactive stone management and blood pressure/renal monitoring. PMC

20. Endocrinology follow-up for vitamin D metabolism. Purpose: guide specialized therapies (e.g., rifampin, azoles). Mechanism: targeted control of vitamin D pathways. PMC+1

---

Drug treatments

Important safety note: No drug is FDA-approved specifically for ARIH. Medicines below are used to treat hypercalcemia or its vitamin-D mechanism. Doses and timing vary by age and kidney function. Always follow a specialist’s plan. FDA citations below are from accessdata.fda.gov for authoritative product information; they do not imply FDA approval for ARIH.

1. Isotonic IV fluids (0.9% saline). Purpose: first-line in acute severe hypercalcemia to expand volume and enhance renal calcium excretion. Mechanism: increases filtered load and urinary calcium. Time: continuous infusion in hospital until stable. Side effects: fluid overload risk. Evidence is standard hypercalcemia management. NCBI

2. Furosemide (loop diuretic) after rehydration. Class: loop diuretic. Typical pediatric dosing is individualized. Time: intermittent after fluids. Purpose: increase calciuresis. Mechanism: blocks NKCC2 in thick ascending limb, decreasing calcium reabsorption. Key label safety: electrolyte losses, ototoxicity at high doses. FDA Access Data+1

3. Calcitonin-salmon (Miacalcin®). Class: hormone. Time: rapid but short-lived calcium lowering. Purpose: quick bridge while other measures act. Mechanism: inhibits osteoclasts and reduces renal calcium reabsorption. Side effects: nausea, flushing; tachyphylaxis with repeated dosing. FDA Access Data+1

4. Pamidronate (Aredia®). Class: IV bisphosphonate. Purpose: longer control of calcium by blocking bone resorption. Mechanism: binds bone mineral and inhibits osteoclasts. Time: infusions spaced by response. Side effects: hypocalcemia, flu-like reaction, rare renal effects. FDA Access Data+1

5. Zoledronic acid (Zometa®/Reclast®). Class: potent IV bisphosphonate. Purpose: alternative to pamidronate for sustained calcium control. Mechanism: strong osteoclast inhibition. Time: single infusion with monitoring. Side effects: hypocalcemia, renal toxicity, osteonecrosis of jaw (rare). FDA Access Data+1

6. Glucocorticoids (prednisone/prednisolone; Orapred®, RAYOS®). Class: corticosteroids. Purpose: reduce vitamin-D–mediated hypercalcemia in some causes; effect in CYP24A1 deficiency may be limited but sometimes tried. Mechanism: decreases 1,25-OH2-D production in granulomatous or lymphoma-related hypercalcemia; may blunt gut calcium absorption. Time: short courses. Side effects: immunosuppression, growth effects. FDA Access Data+2FDA Access Data+2

7. Rifampin (Rifadin®). Class: enzyme inducer antibiotic. Purpose: targeted metabolic therapy in CYP24A1 deficiency by inducing CYP3A4, an alternate pathway to inactivate vitamin D metabolites. Mechanism: increases 4-hydroxylation of calcitriol; improves hypercalcemia and hypercalciuria in case series. Time: daily with careful monitoring and interaction checks. Side effects: hepatotoxicity, drug interactions, orange discoloration of secretions. Label notes induction of vitamin D metabolism. PMC+2PubMed+2

8. Fluconazole (Diflucan®). Class: azole antifungal. Purpose: inhibit vitamin D activation indirectly; case reports show lower calcium and urinary calcium in CYP24A1 deficiency using low-dose regimens. Mechanism: reduces activity of 1-alpha hydroxylase and/or P450 pathways involved in vitamin D metabolism. Time: daily; monitor LFTs and QT risk. Side effects: hepatotoxicity, drug interactions. PMC+2FDA Access Data+2

9. Ketoconazole (Nizoral®). Class: azole antifungal. Purpose: older agent that inhibits steroidogenic and vitamin D-related P450s; occasionally used short-term. Mechanism: broad P450 inhibition lowers calcitriol generation. Side effects: significant hepatotoxicity and adrenal effects limit use; careful monitoring needed. FDA Access Data+2FDA Access Data+2

10. Denosumab (Prolia®). Class: RANKL antibody. Purpose: rescue therapy when bisphosphonates are unsuitable (e.g., renal impairment). Mechanism: blocks osteoclast formation and function. Time: subcutaneous dosing with calcium/Vit D precautions; pediatric safety concerns exist. Side effects: hypocalcemia risk, especially in kidney disease; recent label updates warn about pediatric complications. FDA Access Data+1

11. Phosphate supplements (clinician-directed) in SLC34A1 disease. Class: electrolyte therapy. Purpose: correct phosphate wasting to reduce calcitriol drive and calm hypercalcemia. Mechanism: restores phosphate pool; often as oral preparations. (FDA labeling exists for parenteral potassium phosphate; oral products vary.) e-apem.org

12. Potassium citrate (stone prevention context). Class: urinary alkalinizer/citrate donor. Purpose: raise urinary citrate to reduce calcium stone risk. Mechanism: citrate binds calcium and reduces crystal formation. Use is extrapolated from stone prevention practice. NCBI

13. Magnesium repletion if low. Class: mineral supplement. Purpose: correct cofactor deficits that can affect PTH and renal handling. Mechanism: normalizes mineral balance; individualized dosing. NCBI

14. Short-term antiemetics for symptomatic relief. Purpose: support hydration by controlling vomiting during hypercalcemia flares. Mechanism: symptom control; no direct effect on calcium. NCBI

15. Proton pump inhibitor during high-dose steroids or stress. Purpose: reduce GI risk. Mechanism: lowers gastric acid; supportive only. NCBI

16. Analgesics without calcium content for stone pain (clinician-selected). Purpose: comfort and hydration adherence. Mechanism: symptom relief; avoid NSAID overuse in dehydration. NCBI

17. Antibiotic stewardship with rifampin. Purpose: manage interactions if rifampin is chosen for CYP24A1; adjust other drugs. Mechanism: CYP3A induction affects many medicines. Label emphasizes interactions. FDA Access Data

18. Electrolyte-guided diuresis. Purpose: tailor furosemide with potassium and magnesium supplementation when needed. Mechanism: avoid arrhythmia and weakness from losses. FDA Access Data

19. Temporary formula modifications only under specialist care. Purpose: control calcium/vitamin D intake in infants while ensuring growth. Mechanism: supervised nutritional adjustments. MDPI

20. Follow a written hypercalcemia action plan. Purpose: early lab checks and fluid plan at first signs. Mechanism: reduces ER visits and kidney injury. NCBI

---

Dietary molecular supplements

1. Oral phosphate salts (when SLC34A1-related). Dose: individualized across age and labs. Function: replenish phosphate to reduce calcitriol drive. Mechanism: corrects renal phosphate wasting to calm vitamin D over-activation. e-apem.org

2. Citrate (e.g., potassium citrate). Dose: per weight and urine citrate targets. Function: stone prevention. Mechanism: citrate binds urinary calcium and increases solubility, lowering stone risk. NCBI

3. Magnesium (if low). Dose: lab-guided. Function: supports PTH physiology and renal handling of calcium. Mechanism: cofactor for many enzymes; deficiency can worsen mineral imbalance. NCBI

4. Electrolyte solutions (oral rehydration). Dose: frequent small volumes. Function: maintain hydration to aid calciuresis. Mechanism: supports urine flow and prevents prerenal azotemia. NCBI

5. Omega-3 fatty acids (adjunctive). Dose: standard pediatric-safe dosing. Function: general anti-inflammatory support; no direct calcium effect but may support renal health. Mechanism: membrane effects; adjunct only. NCBI

6. Probiotics (adjunctive). Dose: OTC per product; discuss with clinician. Function: gut health during dietary restriction or antibiotics (e.g., rifampin). Mechanism: microbiome support; no direct effect on calcium. FDA Access Data

7. Low-oxalate diet guidance (dietary pattern rather than a pill). “Supplement” here means structured intake kit (meal replacements) if diet is very limited; clinician-led. Function: reduce calcium oxalate stone risk. Mechanism: lower oxalate load. NCBI

8. B-complex/folate (general nutrition) when intake is poor. Function: cover micronutrient gaps during restricted diets. Mechanism: general support; does not treat calcium itself. NCBI

9. Sodium bicarbonate (rare adjunct) if metabolic acidosis from vomiting/dehydration is present. Function: correct acid-base to protect kidneys. Mechanism: alkalinization; clinician-directed. NCBI

10. Protein energy supplements (dietitian-supervised) in failure-to-thrive. Function: safe growth while minerals are controlled. Mechanism: adequate calories with careful mineral content. PMC

---

Immunity booster / regenerative / stem-cell drugs

There are no FDA-approved “immunity booster,” regenerative, or stem-cell drugs for ARIH. Using such products for this condition is not evidence-based and could be unsafe. Instead, specialists use targeted therapies that change vitamin D metabolism (e.g., rifampin, fluconazole, ketoconazole) or control bone resorption (bisphosphonates, denosumab) with careful monitoring. I can list six evidence-based targeted medicines already discussed—rifampin, fluconazole, ketoconazole, pamidronate, zoledronic acid, and calcitonin—with FDA labeling links above—but these are not “immunity boosters” or stem-cell agents. Please rely on your specialist’s plan. FDA Access Data+5FDA Access Data+5FDA Access Data+5

---

Surgeries

Surgery is not used to treat ARIH itself. Procedures address complications such as kidney stones or obstructive uropathy. Options include (1) ureteroscopy with laser lithotripsy, (2) shock-wave lithotripsy, (3) percutaneous nephrolithotomy, (4) stent placement for obstruction, and (5) nephrostomy in severe cases. These aim to clear stones, relieve blockage, and protect kidney function. Prevention and metabolic control remain most important. NCBI

---

Preventions

1. Avoid vitamin D supplements unless your specialist prescribes them.

2. Moderate sun exposure.

3. Keep good daily hydration.

4. Avoid thiazide diuretics unless a specialist advises otherwise.

5. Review all medicines for interactions (especially if on rifampin).

6. Keep regular endocrinology and nephrology follow-ups.

7. Use nutritionist support to manage calcium and fortified foods.

8. Monitor urine calcium periodically.

9. Use kidney ultrasound as advised.

10. Have a written plan for illness-related dehydration. NCBI+3MDPI+3PMC+3

---

When to see doctors

Seek urgent care if there is poor feeding, vomiting, severe constipation, marked lethargy, little urine, or signs of dehydration. These may mark a hypercalcemia flare. Also contact your team for new flank pain (possible stones), blood in urine, fever with dehydration, or if a new medicine is started that may interact with rifampin or steroids. Regular visits are key for growth checks, labs, and imaging. NCBI

---

What to eat and what to avoid

During active disease, your clinician may advise temporarily limiting very high-calcium foods and all vitamin-D–fortified products. Focus on hydration, balanced calories, and safe mineral targets. Avoid over-the-counter vitamin D, calcium-containing antacids, and high-dose “bone health” products. When stable, the team may relax some limits but will continue to avoid unnecessary vitamin D. Stone-prevention habits (fluids, citrate-containing foods like lemon/lime) may help. MDPI+1

---

Frequently asked questions (FAQs)

1) Is ARIH always diagnosed in babies?
No. It often starts in infancy but some people present later with kidney stones or nephrocalcinosis and otherwise unexplained hypercalcemia; genetics then reveals CYP24A1 or SLC34A1 variants. Karger Publishers+1

2) What is the key lab clue?
High calcium, low or suppressed PTH, and high or inappropriately normal 1,25-dihydroxy-vitamin D, with high urine calcium. OUP Academic

3) Does sunlight matter?
Yes. Moderating UV-B exposure helps because skin makes vitamin D, which worsens calcium in CYP24A1 deficiency. MDPI

4) Why are thiazides avoided?
They raise renal calcium reabsorption and can worsen hypercalcemia. PMC

5) Do steroids always work?
Not always in CYP24A1 deficiency, but they are sometimes used in vitamin-D–mediated hypercalcemia and may be trialed short-term with monitoring. NCBI

6) What is special about rifampin here?
It turns on CYP3A4, a backup enzyme that can inactivate vitamin D metabolites when CYP24A1 is broken; case series show clinical improvement. PMC+1

7) Are azoles like fluconazole useful?
Low-dose fluconazole has reduced calcium and urinary calcium in case reports by dampening vitamin-D–activating pathways. Safety monitoring is required. PMC

8) What about ketoconazole?
It can inhibit steroid and vitamin D P450 enzymes but has significant liver toxicity concerns, so use is limited and carefully monitored. FDA Access Data

9) Why use bisphosphonates?
They slow bone resorption to lower calcium when levels are high or persistent, buying time while vitamin D metabolism is addressed. FDA Access Data+1

10) Is denosumab an option?
Sometimes, especially if kidney function limits bisphosphonates, but hypocalcemia risks and pediatric safety issues require caution. FDA Access Data+1

11) Do all carriers get symptoms?
No. Biallelic variants cause classic disease. However, some studies suggest even monoallelic variants can be symptomatic, often with milder features—this remains an area of research. BioMed Central

12) Can adults have ARIH?
Yes. Adults may present with nephrolithiasis or hypercalcemia and later be found to have CYP24A1 mutations. PMC

13) Is pregnancy management different?
Yes. Strict vitamin D avoidance and careful calcium monitoring are emphasized; evidence consists of case reports and expert opinion. MDPI

14) Is there a curative genetic therapy?
No approved gene therapy exists. Management focuses on controlling vitamin D metabolism, calcium level, and kidney risks. OUP Academic

15) What is the long-term outlook?
With early diagnosis, careful mineral control, hydration, and kidney monitoring, many children do well; kidney calcifications and stones need ongoing surveillance. PMC

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: October 07, 2025.